U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H11NO.C4H6O4
Molecular Weight 255.2671
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMOXYPINE SUCCINATE

SMILES

OC(=O)CCC(O)=O.CCC1=NC(C)=CC=C1O

InChI

InChIKey=IKMNOGHPKNFPTK-UHFFFAOYSA-N
InChI=1S/C8H11NO.C4H6O4/c1-3-7-8(10)5-4-6(2)9-7;5-3(6)1-2-4(7)8/h4-5,10H,3H2,1-2H3;1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H11NO
Molecular Weight 137.179
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Emoxypine (ethylmethylhydroxypyridine) succinate (MEXIDOL®) is a 3-hydroxypyridine derivative which is quite similar in structure to Vitamin B6 (pyridoxine). The most important components of the mechanism of action of Mexidol® are its antioxidant and membranotropic effects, the ability to modulate functioning of receptors and membrane-bound enzymes, restore a neurotransmitter balance. Due to its mechanism of action Mexidol® has a wide range of pharmacological effects, realized on at least two levels – neuronal and vascular. It has antihypoxic, anti-ischemic, neuroprotective, nootropic, vegetotrophic, anti-stress, anxiolytic, anticonvulsant, anti-alcohol, cardioprotective, anti-atherogenic, geroprotective and other actions. Under the action of Mexidol®, it is observed an improvement in cerebral circulation and microcirculation. Emoxypine is distributed in Russia but it is widely unknown in other regions.

Originator

Curator's Comment: In early 1980s, in State Institution Research Institute of Pharmacology of RAMS, by L.D. Smirnov and V.I. Kuzmin, 2-ethyl-6-methyl-3-hydroxypyridine succinate was synthesized, and under supervision of Academician of RAMS A.V. Valdman, its pharmacological effects were found, the mechanism of action was studied, preclinical studies on toxicology and pharmacokinetics were carried out, the Mexidol® trademark was identified, the drug was registered in the USSR Ministry of Healthcare, the first clinical trials and introduction of the preparation into medical practice were carried out.

Approval Year

PubMed

PubMed

TitleDatePubMed
[Mexidol potentiates antiparkinsonian effect of L-DOPA in MPTP-induced parkinsonism model].
2001 Jan-Feb
[Relation between mexidol glucuronide conjugation and characteristics of its therapeutic effect in patients with organic lesions in the central nervous system].
2001 May-Jun
[Cardioprotective effect of drugs with antioxidant activity in acute cerebral ischemia].
2001 Nov-Dec
[Effect of nootropic agents on impulse activity of cerebral cortex neurons].
2001 Nov-Dec
[Prognostic significance of local and systemic indicators of lipid peroxidation and antioxidant system in perforating wounds of the eyes and their time course during local antioxidant treatment].
2001 Sep-Oct
[Effect of mexidol on oxidative stress in cerebral variant of hypertensive crisis].
2002
[The effect of some medications used in the treatment of cerebrovascular diseases on free radical oxidation in the model systems].
2002
[Effect of emoxypine on myocardial electrical instability and homeostasis parameters in patients with acute disturbance of cerebrovascular circulation].
2002 May-Jun
The action of mexidol on the state of conditioned reflex activity after traumatic brain lesions.
2003 Feb
GABAergic system in the anxiolytic effect of Proproten: experimental study.
2003 Jan
[Model corasol-induced seizures are followed by increase of nitric oxide generation and are abolished by mexidol and alpha-tocopherol].
2003 Jul-Aug
The influence of anticonvulsant and antioxidant drugs on nitric oxide level and lipid peroxidation in the rat brain during penthylenetetrazole-induced epileptiform model seizures.
2003 May
[Effect of low intensity laser light in the red range on macrophage superoxide dismutase activity].
2003 May-Jun
[Emoxipin in combined pharmacological defense of the kidney from ischemia and operative stress (an experimental study)].
2003 Sep-Oct
[Efficacy of emoxypine in combined therapy for elderly patients with postinfarct cardiosclerosis and heart failure].
2004
[Use of mexidol in stomatology: results and perspectives].
2004
[Efficacy of cytoprotective agent Mexicor in urgent cardiology].
2004
[Protective effect of activators of biological oxidation in nitrite intoxication in rats].
2005
[The treatment of patients with toxic encephalopathy caused by using surrogate psychoactive manganese-containing compounds].
2005
[Effects of mexidol on the antioxidative status of patients suffering from coronary heart disease with dislipidemia].
2005
[Methodological bases of early psychosocial rehabilitation of poststroke patients in neurological hospital].
2005
Antihypoxic and antinecrotic effect of mexidol in skin ischemia.
2005 Feb
The effects of Mexidol on the acquisition of food-related conditioned reflexes and synaptic ultrastructure in field CA1 of the rat hippocampus after single acoustic stimuli with ultrasonic components.
2005 May
[Metabolic effects of mexidole during cardiosurgical operations using extracorporeal circulation].
2005 May-Jun
Lymphotropic effect of mexidol in reactive fever.
2005 Oct
Activity of nitric oxide synthase and concentration of nitric oxide end metabolites in the gingiva under experimental pathological conditions.
2005 Oct
[Estimating the potential of antioxidant therapy for patients with Parkinson's disease diagnosis].
2005 Sep-Oct
[The use of mexidol in urgent treatment of drug addiction].
2006
[Mexidol in combined treatment of acute pancreatitis].
2006
[Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy].
2006
[Antioxidant activity of inhibitors of free radical reactions in the dressing materials for wound healing].
2006 Jan-Feb
Effect of mexidol and nitroglycerine on iron-sulfur centers, cytochrome P-450, and nitric oxide formation in liver tissue of experimental animals.
2006 Oct
[The efficacy of complex therapy of ventricular arrhythmias with emoxipin and preductal in combination with antiarrhythmic agents].
2007
[The influence of 3-oxypyridine antioxidants on depression in patients with diabetes mellitus].
2007
Efficacy of neuroprotectors in patients with tension headaches.
2007 Jun
[Pharmacological correction of neuronal damage in sensomotor zone of frontal cortex under conditions of experimental cerebral blood flow pathology].
2007 Nov-Dec
Patents

Patents

Sample Use Guides

Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:14:41 GMT 2023
Edited
by admin
on Fri Dec 15 18:14:41 GMT 2023
Record UNII
2R985002CT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EMOXYPINE SUCCINATE
Common Name English
3-PYRIDINOL, 2-ETHYL-6-METHYL-, BUTANEDIOATE (1:1) (SALT)
Common Name English
Methylethylpiridinol succinate [WHO-DD]
Common Name English
MEXIPRIM
Common Name English
MEXIDOL
Common Name English
METHYLETHYLPIRIDINOL SUCCINATE
WHO-DD  
Common Name English
MEXICOR
Common Name English
BUTANEDIOIC ACID, COMPD. WITH 2-ETHYL-6-METHYL-3-PYRIDINOL (1:1)
Common Name English
EMICIDINE
Common Name English
EMICIDIN
Common Name English
Code System Code Type Description
FDA UNII
2R985002CT
Created by admin on Fri Dec 15 18:14:41 GMT 2023 , Edited by admin on Fri Dec 15 18:14:41 GMT 2023
PRIMARY
CAS
127464-43-1
Created by admin on Fri Dec 15 18:14:41 GMT 2023 , Edited by admin on Fri Dec 15 18:14:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID30155577
Created by admin on Fri Dec 15 18:14:41 GMT 2023 , Edited by admin on Fri Dec 15 18:14:41 GMT 2023
PRIMARY
SMS_ID
100000128270
Created by admin on Fri Dec 15 18:14:41 GMT 2023 , Edited by admin on Fri Dec 15 18:14:41 GMT 2023
PRIMARY
PUBCHEM
122298
Created by admin on Fri Dec 15 18:14:41 GMT 2023 , Edited by admin on Fri Dec 15 18:14:41 GMT 2023
PRIMARY
MESH
C070020
Created by admin on Fri Dec 15 18:14:41 GMT 2023 , Edited by admin on Fri Dec 15 18:14:41 GMT 2023
PRIMARY
EVMPD
SUB35088
Created by admin on Fri Dec 15 18:14:41 GMT 2023 , Edited by admin on Fri Dec 15 18:14:41 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY